{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:00:20Z","timestamp":1791201620432,"version":"4.2.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000058","name":"SAMHSA","doi-asserted-by":"publisher","award":["5H79TI081358-05"],"award-info":[{"award-number":["5H79TI081358-05"]}],"id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["DA007292"],"award-info":[{"award-number":["DA007292"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.drugalcdep.2024.111130","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T14:01:55Z","timestamp":1708696915000},"page":"111130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["\u201cI want to stay here\u201d: Patient and staff perspectives on transitioning from a low-threshold buprenorphine program to clinic-based care"],"prefix":"10.1016","volume":"257","author":[{"given":"Noelle G.","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley Q.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"Nordeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Agus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky L.","family":"Genberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Buresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2024.111130_bib1","unstructured":"Ahmad, F.B., Rossen, L.M., Sutton, P., Cisewski, J.A., 2023. Provisional Drug Overdose Death Counts.\u00a0\u3008https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm\u3009."},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.111130_bib2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/ADM.0000000000000863","article-title":"Toward a typology of office-based buprenorphine treatment laws: themes from a review of state laws","volume":"16","author":"Andraka-Christou","year":"2022","journal-title":"J. Addict. Med."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111130_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12954-023-00775-0","article-title":"Women who use drugs: engagement in practices of harm reduction care","volume":"20","author":"Austin","year":"2023","journal-title":"Harm Reduct. J."},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.111130_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1073110518782934","article-title":"Buprenorphine supply, access, and quality: where we have come and the path forward","volume":"46","author":"Breen","year":"2018","journal-title":"J. Law Med. Ethics"},{"issue":"7","key":"10.1016\/j.drugalcdep.2024.111130_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1176\/appi.ps.70701","article-title":"A mobile buprenorphine treatment program for homeless patients with opioid use disorder","volume":"70","author":"Buzza","year":"2019","journal-title":"Psychiatr. Serv."},{"issue":"8","key":"10.1016\/j.drugalcdep.2024.111130_bib6","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792","article-title":"The role of behavioral interventions in buprenorphine maintenance treatment: a review","volume":"174","author":"Carroll","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111130_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13722-019-0149-1","article-title":"Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco","volume":"14","author":"Carter","year":"2019","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib8","series-title":"Constructing Grounded Theory","author":"Charmaz","year":"2006"},{"key":"10.1016\/j.drugalcdep.2024.111130_bib9","unstructured":"Drug Enforcement Administration, 2021. Registration Requirements for Narcotic Treatment Programs With Mobile Components.\u00a0\u3008https:\/\/www.govinfo.gov\/content\/pkg\/FR-2021-06-28\/pdf\/2021-13519.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsat.2019.08.002","article-title":"Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2\u202fyears: results from a multisite randomized trial of adults with opioid use disorder","volume":"106","author":"Evans","year":"2019","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jsat.2018.08.012","article-title":"Health insurance coverage is associated with access to substance use treatment among individuals with injection drug use: evidence from a 12-year prospective study","volume":"96","author":"Feder","year":"2019","journal-title":"J. Subst. Abus. Treat."},{"issue":"3","key":"10.1016\/j.drugalcdep.2024.111130_bib12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1353\/hpu.2014.0139","article-title":"Health outcomes and retention in care following release from prison for patients of an urban post-incarceration transitions clinic","volume":"25","author":"Fox","year":"2014","journal-title":"J. Health Care Poor Underserved"},{"issue":"3","key":"10.1016\/j.drugalcdep.2024.111130_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamapsychiatry.2021.3716","article-title":"Methadone on wheels-a new option to expand access to care through mobile units","volume":"79","author":"Gibbons","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111130_bib14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2307\/798843","article-title":"The constant comparative method of qualitative analysis","volume":"12","author":"Glaser","year":"1965","journal-title":"Soc. Probl."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cct.2016.12.015","article-title":"Extended-release naltrexone for pre-release prisoners: a randomized trial of medical mobile treatment","volume":"53","author":"Gordon","year":"2017","journal-title":"Contemp. Clin. Trials"},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111130_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/07853890.2021.2022188","article-title":"Awareness, perception and utilization of a mobile health clinic by people who use drugs","volume":"54","author":"Grieb","year":"2022","journal-title":"Ann. Med."},{"issue":"12","key":"10.1016\/j.drugalcdep.2024.111130_bib17","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2105\/AJPH.2016.303483","article-title":"Is the prescription opioid epidemic a white problem?","volume":"106","author":"Hansen","year":"2016","journal-title":"Am. J. Public Health"},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.111130_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/10826084.2017.1385633","article-title":"At the expense of a life: race, class, and the meaning of buprenorphine in pharmaceuticalized \"care\"","volume":"53","author":"Hatcher","year":"2018","journal-title":"Subst. Use Misuse"},{"issue":"Suppl 3","key":"10.1016\/j.drugalcdep.2024.111130_bib19","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.1093\/infdis\/jiac267","article-title":"HIV treatment outcomes in POP-UP: drop-in HIV primary care model for people experiencing homelessness","volume":"226","author":"Hickey","year":"2022","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.drugalcdep.2024.111130_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/08897077.2019.1635557","article-title":"Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington","volume":"41","author":"Hood","year":"2020","journal-title":"Subst. Abus."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108315","article-title":"The Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN-PATHS): a hybrid type-1 effectiveness trial of enhanced primary care to improve opioid use disorder treatment outcomes following release from jail","volume":"128","author":"Howell","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"issue":"6","key":"10.1016\/j.drugalcdep.2024.111130_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/ajad.13055","article-title":"Mobile, community-based buprenorphine treatment for veterans experiencing homelessness with opioid use disorder: a pilot, feasibility study","volume":"29","author":"Iheanacho","year":"2020","journal-title":"Am. J. Addict."},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.111130_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib24","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug Alcohol Depend. Rep."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","article-title":"Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap","volume":"103","author":"Krawczyk","year":"2019","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108074","article-title":"Lessons from COVID 19: are we finally ready to make opioid treatment accessible?","volume":"117","author":"Krawczyk","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int. J. Drug Policy"},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111130_bib28","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/08897077.2021.1876202","article-title":"\"It's a place that gives me hope\": a qualitative evaluation of a buprenorphine-naloxone group visit program in an urban federally qualified health center","volume":"42","author":"Lai","year":"2021","journal-title":"Subst. Abus."},{"issue":"3","key":"10.1016\/j.drugalcdep.2024.111130_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111130_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12875-019-1047-z","article-title":"Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review","volume":"20","author":"Louie","year":"2019","journal-title":"BMC Fam. Pract."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109915","article-title":"\"Come try it out. Get your foot in the door:\" exploring patient perspectives on low-barrier treatment for opioid use disorder","volume":"248","author":"Lowenstein","year":"2023","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.111130_bib32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/ADM.0000000000000967","article-title":"Use of a telemedicine bridge clinic to engage patients in opioid use disorder treatment","volume":"16","author":"Lynch","year":"2022","journal-title":"J. Addict. Med."},{"issue":"Suppl 3","key":"10.1016\/j.drugalcdep.2024.111130_bib33","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: a rapid review","volume":"35","author":"Mackey","year":"2020","journal-title":"J. Gen. Intern. Med."},{"issue":"11","key":"10.1016\/j.drugalcdep.2024.111130_bib34","doi-asserted-by":"crossref","first-page":"821","DOI":"10.7326\/L19-0145","article-title":"The next stage of buprenorphine care for opioid use disorder","volume":"170","author":"Martin","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"14","key":"10.1016\/j.drugalcdep.2024.111130_bib35","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMp2000227","article-title":"Stigma reduction to combat the addiction crisis - developing an evidence base","volume":"382","author":"McGinty","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib36","article-title":"Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago","volume":"150","author":"Messmer","year":"2023","journal-title":"J. Subst. Use Addict. Treat."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111130_bib37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/ADM.0b013e318233d621","article-title":"Comparison of buprenorphine treatment for opioid dependence in 3 settings","volume":"6","author":"Miotto","year":"2012","journal-title":"J. Addict. Med."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111130_bib38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11606-020-06201-6","article-title":"\"Health is on the back burner:\" Multilevel barriers and facilitators to primary care among people who inject drugs","volume":"36","author":"Motavalli","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib39","unstructured":"National Institute on Drug Abuse, 2023. Drug Overdose Death Rates.\u00a0\u3008https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates\u3009."},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.111130_bib40","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/ADM.0000000000000774","article-title":"Adapting a low-threshold buprenorphine program for vulnerable populations during the COVID-19 pandemic","volume":"15","author":"Nordeck","year":"2021","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib41","unstructured":"NVivo, 2020. Lumivero.\u00a0\u3008www.lumivero.com\u3009."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108342","article-title":"Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting","volume":"127","author":"O'Gurek","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"issue":"9","key":"10.1016\/j.drugalcdep.2024.111130_bib43","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2024.111130_bib44","article-title":"Higher buprenorphine dose associated with increased treatment retention at low threshold buprenorphine clinic: a retrospective cohort study","volume":"147","author":"Selitsky","year":"2023","journal-title":"J. Subst. Use Addict. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.09.003","article-title":"Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: a qualitative study of a bridge clinic","volume":"107","author":"Snow","year":"2019","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108900","article-title":"Not in my treatment center: leadership's perception of barriers to MOUD adoption","volume":"144","author":"Stewart","year":"2023","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108627","article-title":"The role of stigma in U.S. primary care physicians' treatment of opioid use disorder","volume":"221","author":"Stone","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104214","article-title":"Get in and get out, get on with life\": patient and provider perspectives on methadone van implementation for opioid use disorder treatment","volume":"121","author":"Suen","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2024.111130_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108410","article-title":"Bridge clinic buprenorphine program decreases emergency department visits","volume":"130","author":"Sullivan","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib50","series-title":"Undoing Drugs: How Harm Reduction Is Changing the Future of Drugs and Addiction","author":"Szalavitz","year":"2021"},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111130_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13722-023-00365-2","article-title":"Substance use disorder bridge clinics: models, evidence, and future directions","volume":"18","author":"Taylor","year":"2023","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"Red Flags' and 'Red Tape': telehealth and pharmacy-level barriers to buprenorphine in the United States","volume":"105","author":"Textor","year":"2022","journal-title":"Int. J. Drug Policy"},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111130_bib53","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/08897077.2020.1846664","article-title":"A hospital-wide initiative to redesign substance use disorder care: impact on pharmacotherapy initiation","volume":"42","author":"Wakeman","year":"2021","journal-title":"Subst. Abus."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108848","article-title":"Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic","volume":"141","author":"Wakeman","year":"2022","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108149","article-title":"Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: an adaptation to the COVID-19 emergency","volume":"120","author":"Wenzel","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108923","article-title":"Adjunct interventions to standard medical management of buprenorphine in outpatient settings: a systematic review of the evidence","volume":"228","author":"Wyse","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2024.111130_bib57","series-title":"Qualitative Research from Start to Finish","author":"Yin","year":"2015"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871624000516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871624000516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:32:12Z","timestamp":1759829532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871624000516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":57,"alternative-id":["S0376871624000516"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111130","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cI want to stay here\u201d: Patient and staff perspectives on transitioning from a low-threshold buprenorphine program to clinic-based care","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111130"}}